1. AN12855 is efficacious in acute and chronic murine models of TB infection.
AN12855 is efficacious in acute and chronic murine models of TB infection. (A, B) In vivo efficacy in a murine GKO (C57BL/6-Ifngtm1Ts) model of acute TB. Compounds were dosed orally daily for 9 d after 14 d of infection (start) with a low-dose aerosol of M. tuberculosis Erdman. Mean (A) lung and (B) spleen log10 CFUs were determined from five mice at the start of treatment and 1 d following the last day of dosing. (B, C) In vivo efficacy in a murine BALB/c model of chronic TB infection. Compounds were dosed orally 5 d a week for 8 weeks after infection with Erdman with a low-dose aerosol 27 d prior (start). Mean (B) lung and (C) spleen log10 CFUs were determined from five to six mice at the start of treatment and following 2, 4, and 8 weeks of treatment. For (A–D), statistical analysis was performed as described in the Materials and Methods section; *P < 0.05.
Yi Xia et al. LSA 2018;1:e
© 2018 Xia et al.